{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:49:20Z","timestamp":1777934960976,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002424","name":"Fujifilm Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014421","name":"EA Pharma Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K09921"],"award-info":[{"award-number":["17K09921"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H02645"],"award-info":[{"award-number":["18H02645"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H02835"],"award-info":[{"award-number":["18H02835"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K16103"],"award-info":[{"award-number":["18K16103"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19ck0106331"],"award-info":[{"award-number":["JP19ck0106331"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.biopha.2020.110330","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:26:07Z","timestamp":1591161967000},"page":"110330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells"],"prefix":"10.1016","volume":"128","author":[{"given":"Naoyuki","family":"Tange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koya","family":"Odaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyasu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seitaro","family":"Terakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.biopha.2020.110330_bib0005","doi-asserted-by":"crossref","first-page":"9366","DOI":"10.1073\/pnas.93.18.9366","article-title":"Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors","volume":"93","author":"Molkentin","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.biopha.2020.110330_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0968-0004(01)02031-X","article-title":"MEF2: a calcium-dependent regulator of cell division, differentiation and death","volume":"27","author":"McKinsey","year":"2002","journal-title":"Trends Biochem. Sci."},{"issue":"23","key":"10.1016\/j.biopha.2020.110330_bib0015","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1242\/dev.008367","article-title":"MEF2: a central regulator of diverse developmental programs","volume":"134","author":"Potthoff","year":"2007","journal-title":"Development"},{"issue":"5","key":"10.1016\/j.biopha.2020.110330_bib0020","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2015-04-643270","article-title":"Essential control of early B-cell development by Mef2 transcription factors","volume":"127","author":"Herglotz","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2020.110330_bib0025","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/0008-5472.CAN-13-2171","article-title":"Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes","volume":"74","author":"Ma","year":"2014","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2020.110330_bib0030","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jnr.23628","article-title":"Overexpression of miR-18a negatively regulates myocyte enhancer factor 2D to increase the permeability of the blood-tumor barrier via Kruppel-like factor 4-mediated downregulation of zonula occluden-1, claudin-5, and occludin","volume":"93","author":"Zhao","year":"2015","journal-title":"J. Neurosci. Res."},{"issue":"5","key":"10.1016\/j.biopha.2020.110330_bib0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.3535","article-title":"Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults","volume":"48","author":"Yasuda","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2020.110330_bib0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","article-title":"Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia","volume":"8","author":"Liu","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2020.110330_bib0045","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.biopha.2020.110330_bib0050","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/s41388-018-0573-9","article-title":"Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity","volume":"38","author":"Hirano","year":"2019","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.biopha.2020.110330_bib0055","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V77.11.2463.2463","article-title":"Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice","volume":"77","author":"Cesano","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2020.110330_bib0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0609.2009.01387.x","article-title":"BCR-ABL-independent and RAS \/ MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4","volume":"84","author":"Suzuki","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110330_bib0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-4608(97)00260-4","article-title":"Establishment of a novel cell line (TS-2) of pre-B acute lymphoblastic leukemia with a t(1;19) not involving the E2A gene","volume":"101","author":"Yoshinari","year":"1998","journal-title":"Cancer Genet. Cytogenet."},{"issue":"4","key":"10.1016\/j.biopha.2020.110330_bib0070","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1535-6108(04)00082-0","article-title":"Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis","volume":"5","author":"Hayakawa","year":"2004","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.biopha.2020.110330_bib0075","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/sj.leu.2403684","article-title":"Cloning and functional characterization of MEF2D\/DAZAP1 and DAZAP1\/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia","volume":"19","author":"Prima","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.biopha.2020.110330_bib0080","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1074\/jbc.M509471200","article-title":"Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation","volume":"281","author":"Gregoire","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.biopha.2020.110330_bib0085","doi-asserted-by":"crossref","first-page":"18534","DOI":"10.1074\/jbc.M001573200","article-title":"Big mitogen-activated kinase regulates multiple members of the MEF2 protein family","volume":"275","author":"Kato","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"5910","key":"10.1016\/j.biopha.2020.110330_bib0090","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.1166088","article-title":"Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy","volume":"323","author":"Yang","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2020.110330_bib0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.cdd.4401160","article-title":"Many cuts to ruin: a comprehensive update of caspase substrates","volume":"10","author":"Fischer","year":"2003","journal-title":"Cell Death Differ."},{"issue":"Pt 2","key":"10.1016\/j.biopha.2020.110330_bib0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1042\/bj3500563","article-title":"Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8","volume":"350","author":"Stennicke","year":"2000","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.biopha.2020.110330_bib0105","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/bioinformatics\/btq043","article-title":"Cascleave: towards more accurate prediction of caspase substrate cleavage sites","volume":"26","author":"Song","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2020.110330_bib0110","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Juarez-Salcedo","year":"2019","journal-title":"Drugs Context"},{"issue":"5971","key":"10.1016\/j.biopha.2020.110330_bib0115","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"6168","key":"10.1016\/j.biopha.2020.110330_bib0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biopha.2020.110330_bib0125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"6336","key":"10.1016\/j.biopha.2020.110330_bib0130","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.biopha.2020.110330_bib0135","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1096\/fj.10-177527","article-title":"Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1","volume":"25","author":"Manns","year":"2011","journal-title":"FASEB J."},{"issue":"26","key":"10.1016\/j.biopha.2020.110330_bib0140","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1038\/sj.onc.1204436","article-title":"Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms","volume":"20","author":"Belmokhtar","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2020.110330_bib0145","unstructured":"S. Tsuzuki, T. Yasuda, S. Kojima, M. Kawazu, K. Akahane, T. Inukai, M. Imaizumi, T. Morishita, K. Miyamura, T. Ueno, S. Karnan, A. Ota, T. Hyodo, H. Konishi, M. Sanada, H. Nagai, K. Horibe, A. Tomita, K. Suzuki, H. Muramatsu, Y. Takahashi, Y. Miyazaki, I. Matsumura, H. Kiyoi, Y. Hosokawa, H. Mano, F. Hayakawa, Targeting MEF2D-fusion oncogenic transcriptional circuitries in B-cell precursor acute lymphoblastic leukemia, Blood Cancer Discovery, in press."},{"issue":"8","key":"10.1016\/j.biopha.2020.110330_bib0150","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1200\/JCO.2001.19.8.2319","article-title":"Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms","volume":"19","author":"Sausville","year":"2001","journal-title":"J. Clin. Oncol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220305229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220305229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:39:36Z","timestamp":1777689576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220305229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":30,"alternative-id":["S0753332220305229"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110330","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110330"}}